|
Delaware
|
|
22-0790350
|
(State or other jurisdiction of
incorporation or organization)
|
|
(IRS Employer
Identification No.)
|
Title of each class
|
|
Name of each exchange on which registered
|
Common Stock, $0.10 Par Value
|
|
New York Stock Exchange
|
1.000% Notes due 2025
|
|
New York Stock Exchange
|
1.750% Notes due 2035
|
|
New York Stock Exchange
|
Title of each class
|
$2 Convertible Preferred Stock, $1 Par Value
|
Large accelerated filer
x
|
|
Accelerated filer
¨
|
|
Non-accelerated filer
¨
|
|
Smaller reporting company
¨
|
|
Item 1.
|
BUSINESS.
|
|
|
Year Ended December 31,
|
||||||||||
Dollars in Millions
|
|
2015
|
|
2014
|
|
2013
|
||||||
United States
|
|
49
|
%
|
|
49
|
%
|
|
51
|
%
|
|||
Europe
|
|
21
|
%
|
|
23
|
%
|
|
24
|
%
|
|||
Japan
|
|
10
|
%
|
|
6
|
%
|
|
5
|
%
|
|||
China
|
|
4
|
%
|
|
4
|
%
|
|
4
|
%
|
|||
|
|
|
|
|
|
|
||||||
Total Revenues
|
|
$
|
16,560
|
|
|
$
|
15,879
|
|
|
$
|
16,385
|
|
|
|
Total Revenues by Product
|
|
Past or Currently Estimated Year of Basic Exclusivity Loss
|
|||||||||||||||||||
Dollars in Millions
|
|
2015
|
|
2014
|
|
2013
|
|
U.S.
|
|
|
EU
(a)
|
|
|
Japan
|
|
|
China
|
||||||
Virology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Baraclude (entecavir)
|
|
$
|
1,312
|
|
|
$
|
1,441
|
|
|
$
|
1,527
|
|
|
2014
|
(b)
|
|
2011-2016
|
(c)
|
|
2016
|
|
|
--
|
Hepatitis C Franchise
(d)
|
|
1,603
|
|
|
256
|
|
|
—
|
|
|
2028
|
|
|
2027
|
|
|
2028
|
(e)
|
|
++
|
|||
Reyataz (atazanavir sulfate) Franchise
|
|
1,139
|
|
|
1,362
|
|
|
1,551
|
|
|
2017
|
|
|
2017-2019
|
(f)
|
|
2019
|
|
|
2017
|
|||
Sustiva (efavirenz) Franchise
|
|
1,252
|
|
|
1,444
|
|
|
1,614
|
|
|
2017
|
(g)
|
|
2013
|
(h)
|
|
++
|
|
|
++
|
|||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Empliciti (elotuzumab)
(i)
|
|
3
|
|
|
—
|
|
|
—
|
|
|
2026
|
|
|
++
|
|
|
++
|
|
|
++
|
|||
Erbitux* (cetuximab)
|
|
501
|
|
|
723
|
|
|
696
|
|
|
2016
|
(j)
|
|
++
|
|
|
2016
|
(k)
|
|
++
|
|||
Opdivo (nivolumab)
|
|
942
|
|
|
6
|
|
|
—
|
|
|
2027
|
(l)
|
|
2026
|
(l)
|
|
2031
|
(l)
|
|
++
|
|||
Sprycel (dasatinib)
|
|
1,620
|
|
|
1,493
|
|
|
1,280
|
|
|
2020
|
(m)
|
|
^^
|
|
|
2021
|
|
|
2020
|
|||
Yervoy (ipilimumab)
|
|
1,126
|
|
|
1,308
|
|
|
960
|
|
|
2023
|
(n)
|
|
2021
|
(o)
|
|
2023
|
(p)
|
|
++
|
|||
Neuroscience
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Abilify* (aripiprazole)
|
|
746
|
|
|
2,020
|
|
|
2,289
|
|
|
2015
|
(q)
|
|
2014
|
(q)
|
|
++
|
|
|
++
|
|||
Immunoscience
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Orencia (abatacept)
|
|
1,885
|
|
|
1,652
|
|
|
1,444
|
|
|
2019
|
(r)
|
|
2017
|
(s)
|
|
2018
|
(t)
|
|
++
|
|||
Cardiovascular
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Eliquis (apixaban)
|
|
1,860
|
|
|
774
|
|
|
146
|
|
|
2023
|
(u)
|
|
2022
|
(v)
|
|
2026
|
(v)
|
|
^
|
^^
|
In May 2013, Apotex Inc., Actavis Group PTC ehf, Generics [UK] Limited (Mylan) and an unnamed company filed oppositions in the European Patent Office (EPO) seeking revocation of European Patent No. 1169038 (the '038 patent) covering dasatinib, the active ingredient in
Sprycel
. The ‘038 patent is scheduled to expire in April 2020 (excluding potential term extensions). On January 20, 2016, the Opposition Division of the EPO revoked the ‘038 patent. The Company will appeal the EPO’s decision to the EPO Board of Appeal. The ‘038 patent will remain in force pending the outcome of our appeal of the EPO’s decision, and we intend to pursue legal options to defend our intellectual property rights from any future infringement. Refer to “Note 22. Legal Proceedings and Contingencies” for more information.
|
(a)
|
References to the EU throughout this Form 10-K include all member states of the European Union during the year ended December 31, 2015. Basic patent applications have not been filed in all current member states for all of the listed products. In some instances, the date of basic exclusivity loss will be different in various EU member states. For those EU countries where the basic patent was not obtained, there may be data protection available.
|
(b)
|
Baraclude
U.S.: In September 2014, Teva Pharmaceuticals launched a generic version of
Baraclude
and we have experienced a negative impact on U.S. net product sales of
Baraclude
beginning in the fourth quarter of 2014. These actions follow a decision in June 2014 by the U.S. Court of Appeals for the Federal Circuit to uphold a lower court decision invalidating
Baraclude
’s patent in February 2013. In May 2015, the U.S. Supreme Court denied the Company's petition for a
writ of certiorari
. Accordingly, this case is now concluded. For more information about this patent litigation matter, refer to "Item 8. Financial Statements—Note
22
. Legal Proceedings and Contingencies."
|
(c)
|
Baraclude
EU: The composition of matter patent expires in the EU between 2011 and 2016.
|
(d)
|
Exclusivity period relates to the
Daklinza
brand.
|
(e)
|
The composition of matter covering daclatasvir in Japan expires in 2028 including granted patent term extension.
|
(f)
|
Reyataz
EU: Data exclusivity in the EU expired in 2014 and projected market exclusivity expires between 2017 and 2019.
|
(g)
|
Sustiva
U.S.: Exclusivity period relates to the
Sustiva
brand and does not include exclusivity related to any combination therapy. The composition of matter patent for efavirenz in the U.S. expired in 2013 and the method of use patent for the treatment of HIV infection expired in September 2014. Pediatric exclusivity has been granted, which provides an additional six month period of exclusivity added to the term of the patents listed in the Orange Book. In October 2014, the Company announced that it has successfully resolved all outstanding U.S. patent litigation relating to efavirenz and that loss of exclusivity in the U.S. for efavirenz is not expected to occur until December 2017.
|
(h)
|
Sustiva
EU: Exclusivity period relates to the
Sustiva
brand and does not include exclusivity related to any combination therapy. Market exclusivity for
Sustiva
expired in November 2013 in countries in the EU. Data exclusivity for
Sustiva
expired in the EU in 2009.
|
(i)
|
Empliciti
: We have a commercialization agreement with AbbVie Inc. (AbbVie) for
Empliciti
. For more information about our arrangement with AbbVie, refer to “—Alliances” below and “Item 8. Financial Statements—Note
3
. Alliances.” AbbVie owns a patent covering elotuzumab as a composition of matter that expires in 2026 in the U.S. (excluding potential patent term extension) and 2024 in the EU, Japan and China (excluding potential patent term extensions in the EU and Japan).
|
(j)
|
Erbitux*
U.S.: Biologic product approved under a Biologics License Application (BLA). Data exclusivity in the U.S. expires in 2016. There is no patent that specifically claims the composition of matter of cetuximab, the active ingredient in
Erbitux*
. In 2015, the Company transferred its rights, including full commercialization and manufacturing responsibilities of
Erbitux*
in North America to Lilly in return for sales-based royalties. For more information about our arrangement with Lilly, refer to "—Alliances" below and “Item 8. Financial Statements—Note
3
. Alliances.”
|
(k)
|
Erbitux*
Japan: Exclusivity period is based on regulatory data protection. BMS transferred its co-commercialization rights in Japan to Merck KgaA in 2015 in exchange for sales-based royalties.
|
(l)
|
Opdivo
: We jointly own a patent with Ono Pharmaceutical Co., Ltd. (Ono) covering
nivolumab as a composition of matter that expires in 2027 in the U.S. (excluding potential patent term extension) and 2026 in the EU (excluding potential patent term extensions). The composition of matter patent covering nivolumab in Japan expires in 2031 including granted patent term extension.
|
(m)
|
Sprycel
: A patent term extension has been granted in the U.S. extending the term on the basic composition of matter patent covering dasatinib until June 2020. In 2013, the Company entered into a settlement agreement with Apotex regarding a patent infringement suit covering the monohydrate form of dasatinib whereby Apotex can launch its generic dasatinib monohydrate abbreviated New Drug Application product in September 2024, or earlier in certain circumstances. In the U.S., orphan drug exclusivity expired in 2013.
|
(n)
|
Yervoy
U.S.: Exclusivity period is based on regulatory data protection. Data exclusivity expires in the U.S. in 2023. We own a patent covering ipilimumab as a composition of matter that currently expires in 2022 in the U.S. (excluding potential patent term extension).
|
(o)
|
Yervoy
EU: Exclusivity period is based on regulatory data protection. Data exclusivity expires in the EU in 2021. We own a patent covering ipilimumab as a composition of matter that currently expires in 2020 in the EU (excluding potential patent term extensions).
|
(p)
|
Yervoy
Japan: Exclusivity period is based on regulatory data protection. We own a patent covering ipilimumab as a composition of matter that currently expires in 2020 in Japan (excluding potential patent term extension).
|
(q)
|
Abilify*
: Our commercialization rights of
Abilify*
terminated in April 2015 in the U.S. and in June 2014 in the EU.
|
(r)
|
Orencia
U.S.: We have a series of patents covering abatacept and its method of use. In the U.S., a patent term extension has been granted for one of the composition of matter patents, extending the term of the U.S. patent to 2019. Data exclusivity expires in the U.S. in 2017 and the method of use patent expires in 2021.
|
(s)
|
Orencia
EU: In the EU, the composition of matter patent covering abatacept expired in 2012. In the majority of the EU countries, we have applied for supplementary protection certificates and also pediatric extension of the supplementary protection certificates for protection until 2017. Most of these protection certificates have been granted. Data exclusivity expires in the EU in 2017 and the method of use patent expires in 2021.
|
(t)
|
Orencia
Japan: Exclusivity period is based on regulatory data protection.
|
(u)
|
Eliquis
U.S.: The composition of matter patent covering apixaban in the U.S. expires in February 2023 (excluding potential patent term extension). In August 2015, we received a Petition for Inter Partes Review of the composition of matter patent covering apixaban filed at the United States Patent and Trademark Office by the Coalition for Affordable Drugs. For more information about this patent litigation matter, refer to “Item 8. Financial Statements—Note
22
. Legal Proceedings and Contingencies."
|
(v)
|
Eliquis
EU and Japan: The composition of matter patent covering apixaban in the EU expires in 2022. We have applied for supplementary protection certificates. Some of these supplementary protection certificates have been granted and expire in 2026. Data exclusivity in the EU expires in 2021. The composition of matter covering apixaban in Japan expires in 2026 including granted patent term extension.
|
Baraclude
|
Baraclude
is a potent and selective inhibitor of hepatitis B virus that was approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis B virus infection.
Baraclude
was discovered and developed internally.
|
Hepatitis C Franchise
|
Daklinza
(daclatasvir (DCV)) is an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus infection (HCV) and was approved by the FDA for use with Gilead Sciences, Inc.'s (Gilead) sofosbuvir for genotype 3.
|
Reyataz Franchise
|
Reyataz
is a protease inhibitor for the treatment of HIV. The
Reyataz Franchise
includes
Reyataz
and combination therapy
Evotaz (
atazanavir 300 mg and cobicistat 150 mg), a once-daily single tablet two drug regimen combining
Reyataz
and Gilead's
Tybost*
(cobicistat) for the treatment of HIV-1 infection in adults.
|
Sustiva Franchise
|
Sustiva
is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV. The
Sustiva Franchise
includes
Sustiva
, an antiretroviral drug used in the treatment of HIV, as well as bulk efavirenz which is included in the combination therapy
Atripla*
(efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), a once-daily single tablet three-drug regimen combining our
Sustiva
and Gilead’s
Truvada*
(emtricitabine and tenofovir disoproxil fumarate). For more information about our arrangement with Gilead, refer to “—Alliances” below and “Item 8. Financial Statements—Note
3
. Alliances.”
|
Empliciti
|
Empliciti
is a humanized monoclonal antibody which was approved by the FDA as a treatment for multiple myeloma and is part of our alliance with AbbVie. Under the terms of the alliance, we were granted exclusive global rights to co-develop and commercialize
Empliciti
. In November 2015, the FDA approved
Empliciti
for the treatment of multiple myeloma as combination therapy with
Revlimid*
and dexamethasone in patients who have received one to three prior therapies.
Revlimid*
is a product of Celgene Corporation. In January 2016, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending that
Empliciti
be granted approval for the treatment of multiple myeloma. We manufacture the bulk requirement for elotuzumab and finish the product in our facilities.
|
Erbitux*
|
Erbitux*
, a biological product,
is an IgG1 monoclonal antibody designed to exclusively target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types as well as some normal cells.
Erbitux*
is approved in combination with irinotecan for the treatment of patients with EGFR-expressing metastatic colorectal cancer (mCRC) who have failed an irinotecan-based regimen and as monotherapy for patients who are intolerant of irinotecan. The FDA approved Erbitux* for use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck and, as a single agent, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed. The FDA also approved Erbitux* for first-line recurrent locoregional or metastatic head and neck cancer in combination with platinum-based chemotherapy with 5-Fluorouracil.
|
Opdivo
|
Opdivo,
a biological product, is a fully human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and natural killer T (NKT) cells. In 2015, the FDA approved
Opdivo
for previously untreated patients with metastatic melanoma, previously treated patients with advanced renal cell carcinoma, and previously treated non-squamous (NSQ) and squamous (SQ) non-small cell lung cancer (NSCLC). In 2015,
Opdivo
received approval in the EU for previously treated SQ NSCLC and first-line and previously treated unresectable or metastatic melanoma. The
Opdivo
+
Yervoy
(ipilimumab) regimen was also approved by the FDA in 2015 for the treatment of BRAF V600 wild-type unresectable or metastatic melanoma. There are several ongoing potentially registrational trials for
Opdivo
in head and neck cancer, hodgkin and non-hodgkin lymphoma and bladder cancer, among other tumor types. Refer to "—Alliances" below and “Item 8. Financial Statements—Note
3
. Alliances” for further discussion of our arrangement with Ono for
Opdivo
in Japan, South Korea and Taiwan.
|
Sprycel
|
Sprycel
is a multi-targeted tyrosine kinase inhibitor approved for the first-line treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase and the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy, including
Gleevec*
(imatinib mesylate).
Gleevec*
is a trademark of Novartis.
|
Yervoy
|
Yervoy,
a biological product, is a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma.
Yervoy
was approved in the U.S. and the EU in 2011 and in Japan in 2015. In 2015, the FDA approved
Yervoy
for the adjuvant treatment of patients with cutaneous melanoma. For more information, about research and development of
Yervoy
, refer to “—Research and Development” below.
|
Abilify*
|
Abilify*
is an atypical antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder and major depressive disorder.
Abilify*
also has pediatric uses in schizophrenia and bipolar disorder, among others.
|
Orencia
|
Orencia
, a biological product, is a fusion protein with novel immunosuppressive activity targeted initially at adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to certain currently available treatments.
Orencia
is available in both an intravenous and subcutaneous formulation in the U.S., Europe and Japan. Refer to "—Alliances" below and “Item 8. Financial Statements—Note
3
. Alliances” for further discussion of our collaborations with Ono for
Orencia
in Japan.
|
Eliquis
|
Eliquis
is an oral Factor Xa inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic (VTE) disorders. Apixaban was discovered internally and is part of our alliance with Pfizer, Inc. (Pfizer). For more information about our alliance with Pfizer, refer to “Item 8. Financial Statements—Note
3
. Alliances.”
|
Immuno-Oncology
|
|
Oncology
|
|
Immunoscience
|
|
Cardiovascular
|
|
Fibrotic Diseases
|
|
Genetically Defined Diseases
|
|
Virology
|
Phase I
|
|
Phase I
|
|
Phase I
|
|
Phase I
|
|
Phase I
|
|
Phase I
|
|
|
Anti-CSF 1R
(a)
|
|
Anti-Fucosyl GM1
|
|
Anti-CD40
|
|
Factor XIa Inhibitors
|
|
Galectin-3 Inhibitor
(f)
|
|
Anti-eTau
(j)
|
|
|
Anti-GITR
|
|
Anti-HER2
(d)
|
|
Anti-CD40L
|
|
PAR4 Antagonist
|
|
PEG-FGF21
|
|
Anti-Myostatin
|
|
|
Anti-LAG3
|
|
BET Inhibitor
|
|
BTK Inhibitor
|
|
|
|
|
|
|
|
|
Lirilumab
(Anti-KIR)
(b)
|
|
Mesothelin-ADC
|
|
TYK2 Inhibitor
|
|
|
|
|
|
|
|
|
Urelumab
(Anti-CD137)
|
|
Ulocuplumab
(Anti-CXCR4)
|
|
Anti-PD-L1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Phase II
|
|
Phase II
|
|
Phase II
|
|
|
|
Phase II
|
|
|
|
|
Lulizumab
(Anti-CD28)
|
|
IKur Inhibitor
|
|
BMS-986020
(LPA1 Antagonist)
(g)
|
|
|
|
BMS-955176
(HIV Maturation Inhibitor)
(k)
|
|
|
|
|
|
|
Nitroxyl Donor
(e)
|
|
PEG-FGF21
(h)
|
|
|
|
|
|
|
|
|
|
|
|
|
Pentraxin-2
(i)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Phase III
|
|
|
|
|
|
|
|
|
|
|
|
Phase III
|
Prostvac*
(c)
|
|
|
|
|
|
|
|
|
|
|
|
Beclabuvir
|
|
|
|
|
|
|
|
|
|
|
|
|
BMS-663068
(HIV Attachment Inhibitor)
(k)
|
(a)
|
Exclusively licensed from Five Prime Therapeutics, Inc.
|
(b)
|
Exclusively licensed from Innate Pharma S.A.
|
(c)
|
Obtained through an exclusive option to license from Bavarian Nordic A/S.
|
(d)
|
Obtained through an exclusive license to acquire F-Star Alpha Ltd.
|
(e)
|
Obtained through acquisition of Cardioxyl Pharmaceuticals, Inc.
|
(f)
|
Obtained through an exclusive option to acquire Galecto Biotech AB.
|
(g)
|
Obtained through the acquisition of Amira Pharmaceuticals, Inc.
|
(h)
|
Exclusively licensed from Ambrx, Inc.
|
(i)
|
Obtained through an exclusive warrant to acquire Promedior, Inc.
|
(j)
|
Obtained through acquisition of iPierian, Inc.
|
(k)
|
Pending sale to ViiV Healthcare.
|
Beclabuvir
|
|
Beclabuvir is an oral small molecule non-nucleoside NS5B inhibitor in regulatory review in Japan for use in combination with DCV and ASV for the treatment of HCV. We own a patent covering Beclabuvir as a composition of matter that expires in 2027 in the U.S.
|
|
|
|
BMS-663068
|
|
BMS-663068 is an investigational compound being studied in HIV-1 which has shown antiviral activity in HIV-1 infected individuals. Attachment inhibitors have a distinct mode of action from other entry inhibitors, which prevent entry of HIV-1 into the host cell following attachment. BMS-663068 is a prodrug which is metabolized to the active basic compound. We hold a patent covering BMS-663068 as a composition of matter that expires in November 2027 in the U.S. BMS-663068 is expected to be sold to ViiV Healthcare in the first half of 2016.
|
|
|
|
Prostvac*
|
|
Prostvac*
is Bavarian Nordic's investigational Phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. BMS has an exclusive option to license and commercialize
Prostvac*
.
|
Key marketed product
|
|
Potential indication and/or formulation
|
|
|
|
Hepatitis C Franchise
|
|
Combination with other antivirals for the treatment of HCV
|
|
|
|
Empliciti
|
|
Additional indication in first-line multiple myeloma
|
|
|
|
Opdivo
|
|
Additional indications in melanoma, renal cell carcinoma (RCC), lung cancer, hodgkin and non-hodgkin lymphoma, head and neck cancer, bladder cancer, glioblastoma, hepatocellular carcinoma, gastric cancer, esophageal cancer in monotherapy and/or in combination with
Yervoy
|
|
|
|
Orencia
|
|
Additional indications in lupus nephritis, psoriatic arthritis, early RA and auto-injector device
|
|
|
|
Eliquis
|
|
Pediatric VTE treatment
|
Hepatitis C Franchise
|
|
Data available from clinical trials
Potential approvals for additional indications |
|
|
|
Empliciti
|
|
Potential approval in multiple myeloma in the EU and Japan
Data available from Phase III study in first-line multiple myeloma
|
|
|
|
Opdivo
|
|
Potential approval in the EU for NSQ NSCLC,
Opdivo
+
Yervoy
combination in melanoma and RCC
Data available from potentially registrational clinical trials in hodgkin and non-hodgkin lymphoma, head and neck cancer, bladder cancer, glioblastoma and lung cancer
Potential submissions in various tumors based on registrational trials.
|
|
|
2015
|
|
2014
|
|
2013
|
McKesson Corporation
|
|
21%
|
|
20%
|
|
19%
|
AmerisourceBergen Corporation
|
|
16%
|
|
17%
|
|
15%
|
Cardinal Health, Inc.
|
|
12%
|
|
12%
|
|
14%
|
Item 1A.
|
RISK FACTORS.
|
Item 1B.
|
UNRESOLVED STAFF COMMENTS.
|
Item 2.
|
PROPERTIES.
|
|
|
Number of Locations
|
|
Square Feet
|
||
United States
|
|
4
|
|
|
2,190,000
|
|
Europe
|
|
3
|
|
|
1,296,000
|
|
Rest of the World
|
|
3
|
|
|
514,000
|
|
Total
|
|
10
|
|
|
4,000,000
|
|
Item 3.
|
LEGAL PROCEEDINGS.
|
Item 4.
|
MINE SAFETY DISCLOSURES.
|
Name and Current Position
|
|
Age
|
|
Employment History for the Past 5 Years
|
|
Giovanni Caforio, M.D.
Chief Executive Officer and Director
Member of the Leadership Team
|
|
51
|
|
|
2010 to 2011 – Senior Vice President, Oncology and Immunology, Global Commercialization
2011 to 2013 – President, U.S. Pharmaceuticals
2013 to 2014 – Executive Vice President and Chief Commercial Officer
2014 to 2015 – Chief Operating Officer and Director of the Company
2015 to present – Chief Executive Officer and Director of the Company
|
Charles Bancroft
Executive Vice President and Chief Financial Officer
Member of the Leadership Team
|
|
56
|
|
|
2010 to 2011 – Chief Financial Officer of the Company
2011 to present – Executive Vice President and Chief Financial Officer of the Company
|
Emmanuel Blin
Senior Vice President and Head of Commercialization, Policy and Operations
Member of the Leadership Team
|
|
46
|
|
|
2010 to 2013 – President & General Manager, Japan
2013 to 2015 – President, Global Commercialization
2015 to present – Senior Vice President, Head of Commercialization, Policy and Operations
|
Joseph C. Caldarella
Senior Vice President and Corporate Controller
|
|
60
|
|
|
2010 to present – Senior Vice President and Corporate Controller
|
Francis Cuss, MB BChir, FRCP
Executive Vice President and Chief Scientific Officer
Member of the Leadership Team
|
|
61
|
|
|
2010 to 2013 – Senior Vice President, Research
2013 to present – Executive Vice President and Chief Scientific Officer
|
John E. Elicker
Senior Vice President, Public Affairs and Investor Relations
Member of the Leadership Team
|
|
56
|
|
|
2010 to 2012 – Senior Vice President, Investor Relations
2012 to present – Senior Vice President, Public Affairs and Investor Relations
|
Murdo Gordon
Senior Vice President and Head of Worldwide Markets
Member of the Leadership Team
|
|
49
|
|
|
2010 to 2011 – Senior Vice President, Access
2011 to 2013 – Senior Vice President, Oncology and Immunology
2013 to 2015 – President, U.S. Pharmaceuticals
2015 to present – Senior Vice President, Head of Worldwide Markets
|
Ann Powell Judge
Senior Vice President, Global Human Resources
Member of the Leadership Team
|
|
50
|
|
|
2009 to 2013 – Chief Human Resources Officer, Shire Pharmaceuticals
2013 to present – Senior Vice President, Global Human Resources
|
Sandra Leung
Executive Vice President and General Counsel
Member of the Leadership Team
|
|
55
|
|
|
2007 to 2014 – General Counsel and Corporate Secretary
2014 to 2015 – Executive Vice President, General Counsel and Corporate Secretary
2015 to present – Executive Vice President and General Counsel
|
Anne Nielsen
Senior Vice President and Chief Compliance and Ethics Officer
Member of the Leadership Team |
|
55
|
|
|
2009 to 2013 – Vice President and Associate General Counsel
2013 to 2013 – Senior Vice President and Deputy General Counsel 2013 to present – Senior Vice President and Chief Compliance and Ethics Officer |
Louis S. Schmukler
President, Global Manufacturing and Supply
Member of the Leadership Team
|
|
60
|
|
|
2009 to 2011 – Senior Vice President, Specialty/Biotechnology Operating Unit, Pfizer
2011 to present – President, Global Manufacturing and Supply
|
Paul von Autenried
Senior Vice President, Enterprise Services and Chief Information Officer
Member of the Leadership Team
|
|
54
|
|
|
2007 to 2011 – Vice President and Chief Information Officer
2011 to 2012 – Senior Vice President and Chief Information Officer
2012 to present – Senior Vice President, Enterprise Services and Chief Information Officer
|
Item 5.
|
MARKET FOR THE REGISTRANT’S COMMON STOCK AND OTHER STOCKHOLDER MATTERS.
|
|
|
2015
|
|
2014
|
||||||||||||
|
|
High
|
|
Low
|
|
High
|
|
Low
|
||||||||
Common:
|
|
|
|
|
|
|
|
|
||||||||
First Quarter
|
|
$
|
68.47
|
|
|
$
|
58.48
|
|
|
$
|
56.61
|
|
|
$
|
48.54
|
|
Second Quarter
|
|
69.15
|
|
|
63.00
|
|
|
52.19
|
|
|
46.59
|
|
||||
Third Quarter
|
|
70.06
|
|
|
57.30
|
|
|
51.96
|
|
|
47.86
|
|
||||
Fourth Quarter
|
|
70.71
|
|
|
59.88
|
|
|
61.30
|
|
|
48.92
|
|
|
|
Common
|
|
Preferred
|
||||||||||||
|
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
First Quarter
|
|
$
|
0.37
|
|
|
$
|
0.36
|
|
|
$
|
0.50
|
|
|
$
|
0.50
|
|
Second Quarter
|
|
0.37
|
|
|
0.36
|
|
|
0.50
|
|
|
0.50
|
|
||||
Third Quarter
|
|
0.37
|
|
|
0.36
|
|
|
0.50
|
|
|
0.50
|
|
||||
Fourth Quarter
|
|
0.37
|
|
|
0.36
|
|
|
0.50
|
|
|
0.50
|
|
||||
|
|
$
|
1.48
|
|
|
$
|
1.44
|
|
|
$
|
2.00
|
|
|
$
|
2.00
|
|
Period
|
|
Total Number of
Shares Purchased
(a)
|
|
Average Price
Paid
per Share
(a)
|
|
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
(b)
|
|
Approximate Dollar Value
of Shares that May Yet Be
Purchased Under the
Plans or Programs
(b)
|
||||||
Dollars in Millions, Except Per Share Data
|
|
|
|
|
|
|
|
|
||||||
January 1 to 31, 2015
|
|
33,737
|
|
|
$
|
59.51
|
|
|
—
|
|
|
$
|
1,368
|
|
February 1 to 28, 2015
|
|
9,178
|
|
|
$
|
60.50
|
|
|
—
|
|
|
$
|
1,368
|
|
March 1 to 31, 2015
|
|
1,825,224
|
|
|
$
|
63.41
|
|
|
—
|
|
|
$
|
1,368
|
|
Three months ended March 31, 2015
|
|
1,868,139
|
|
|
|
|
—
|
|
|
|
||||
April 1 to 30, 2015
|
|
19,294
|
|
|
$
|
63.42
|
|
|
—
|
|
|
$
|
1,368
|
|
May 1 to 31, 2015
|
|
14,672
|
|
|
$
|
64.93
|
|
|
—
|
|
|
$
|
1,368
|
|
June 1 to 30, 2015
|
|
10,387
|
|
|
$
|
66.17
|
|
|
—
|
|
|
$
|
1,368
|
|
Three months ended June 30, 2015
|
|
44,353
|
|
|
|
|
—
|
|
|
|
||||
July 1 to 31, 2015
|
|
13,256
|
|
|
$
|
67.47
|
|
|
—
|
|
|
$
|
1,368
|
|
August 1 to 31, 2015
|
|
8,553
|
|
|
$
|
65.69
|
|
|
—
|
|
|
$
|
1,368
|
|
September 1 to 30, 2015
|
|
5,444
|
|
|
$
|
60.08
|
|
|
—
|
|
|
$
|
1,368
|
|
Three months ended September 30, 2015
|
|
27,253
|
|
|
|
|
—
|
|
|
|
||||
October 1 to 31, 2015
|
|
11,137
|
|
|
$
|
60.48
|
|
|
—
|
|
|
$
|
1,368
|
|
November 1 to 30, 2015
|
|
17,550
|
|
|
$
|
64.53
|
|
|
—
|
|
|
$
|
1,368
|
|
December 1 to 31, 2015
|
|
18,582
|
|
|
$
|
67.52
|
|
|
—
|
|
|
$
|
1,368
|
|
Three months ended December 31, 2015
|
|
47,269
|
|
|
|
|
—
|
|
|
|
||||
Twelve months ended December 31, 2015
|
|
1,987,014
|
|
|
|
|
—
|
|
|
|
(a)
|
Reflects the shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive program.
|
(b)
|
In May 2010, the Board of Directors authorized the repurchase of up to $3.0 billion of common stock. In June 2012, the Board of Directors increased its authorization for the repurchase of common stock by an additional $3.0 billion. The repurchase program does not have an expiration date and we may consider future repurchases.
|
Item 6.
|
SELECTED FINANCIAL DATA.
|
Amounts in Millions, except per share data
|
|
2015
|
|
2014
|
|
2013
|
|
2012
|
|
2011
|
||||||||||
Income Statement Data:
(a)
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Total Revenues
|
|
$
|
16,560
|
|
|
$
|
15,879
|
|
|
$
|
16,385
|
|
|
$
|
17,621
|
|
|
$
|
21,244
|
|
Continuing Operations:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net Earnings
|
|
1,631
|
|
|
2,029
|
|
|
2,580
|
|
|
2,501
|
|
|
5,260
|
|
|||||
Net Earnings Attributable to:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Noncontrolling Interest
|
|
66
|
|
|
25
|
|
|
17
|
|
|
541
|
|
|
1,551
|
|
|||||
BMS
|
|
1,565
|
|
|
2,004
|
|
|
2,563
|
|
|
1,960
|
|
|
3,709
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Net Earnings per Common Share Attributable to BMS:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Basic
|
|
$
|
0.94
|
|
|
$
|
1.21
|
|
|
$
|
1.56
|
|
|
$
|
1.17
|
|
|
$
|
2.18
|
|
Diluted
|
|
$
|
0.93
|
|
|
$
|
1.20
|
|
|
$
|
1.54
|
|
|
$
|
1.16
|
|
|
$
|
2.16
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Average common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Basic
|
|
1,667
|
|
|
1,657
|
|
|
1,644
|
|
|
1,670
|
|
|
1,700
|
|
|||||
Diluted
|
|
1,679
|
|
|
1,670
|
|
|
1,662
|
|
|
1,688
|
|
|
1,717
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash dividends paid on BMS common and preferred stock
|
|
$
|
2,477
|
|
|
$
|
2,398
|
|
|
$
|
2,309
|
|
|
$
|
2,286
|
|
|
$
|
2,254
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash dividends declared per common share
|
|
$
|
1.49
|
|
|
$
|
1.45
|
|
|
$
|
1.41
|
|
|
$
|
1.37
|
|
|
$
|
1.33
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Financial Position Data at December 31:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Cash and cash equivalents
|
|
$
|
2,385
|
|
|
$
|
5,571
|
|
|
$
|
3,586
|
|
|
$
|
1,656
|
|
|
$
|
5,776
|
|
Marketable securities
(b)
|
|
6,545
|
|
|
6,272
|
|
|
4,686
|
|
|
4,696
|
|
|
5,866
|
|
|||||
Total Assets
|
|
31,748
|
|
|
33,749
|
|
|
38,592
|
|
|
35,897
|
|
|
32,970
|
|
|||||
Long-term debt
(b)
|
|
6,550
|
|
|
7,242
|
|
|
7,981
|
|
|
7,232
|
|
|
5,376
|
|
|||||
Equity
|
|
14,424
|
|
|
14,983
|
|
|
15,236
|
|
|
13,638
|
|
|
15,867
|
|
(a)
|
For a discussion of items that affected the comparability of results for the years
2015
,
2014
and
2013
, refer to “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Non-GAAP Financial Measures.”
|
(b)
|
Includes current and non-current portion.
|
|
|
Year Ended December 31,
|
||||||||||
Dollars in Millions, except per share data
|
|
2015
|
|
2014
|
|
2013
|
||||||
Total Revenues
|
|
$
|
16,560
|
|
|
$
|
15,879
|
|
|
$
|
16,385
|
|
Total Expenses
|
|
14,483
|
|
|
13,498
|
|
|
13,494
|
|
|||
Earnings before Income Taxes
|
|
2,077
|
|
|
2,381
|
|
|
2,891
|
|
|||
Provision for Income Taxes
|
|
446
|
|
|
352
|
|
|
311
|
|
|||
Effective tax rate
|
|
21.5
|
%
|
|
14.8
|
%
|
|
10.8
|
%
|
|||
|
|
|
|
|
|
|
||||||
Net Earnings Attributable to BMS
|
|
|
|
|
|
|
||||||
GAAP
|
|
1,565
|
|
|
2,004
|
|
|
2,563
|
|
|||
Non-GAAP
|
|
3,378
|
|
|
3,085
|
|
|
3,019
|
|
|||
|
|
|
|
|
|
|
||||||
Diluted Earnings Per Share
|
|
|
|
|
|
|
||||||
GAAP
|
|
0.93
|
|
|
1.20
|
|
|
1.54
|
|
|||
Non-GAAP
|
|
2.01
|
|
|
1.85
|
|
|
1.82
|
|
|||
|
|
|
|
|
|
|
||||||
Cash, Cash Equivalents and Marketable Securities
|
|
8,930
|
|
|
11,843
|
|
|
8,272
|
|
Product
|
Date
|
Approvals
|
Opdivo
|
December 2015
|
Japanese Ministry of Health, Labour and Welfare manufacturing and marketing approval for patients with unresectable, advanced or recurrent non-small cell lung cancer (NSCLC), received by Ono Pharmaceutical Co., Ltd. (Ono).
|
November 2015
|
U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of previously untreated patients with BRAF V600 wild-type unresectable or metastatic melanoma
|
|
November 2015
|
FDA approval for the treatment of previously treated patients with advanced (metastatic) renal cell carcinoma (RCC)
|
|
October 2015
|
FDA approval for the treatment of previously treated patients with non-squamous (NSQ) NSCLC
|
|
July 2015
|
EU approval for the treatment of locally advanced or metastatic squamous (SQ) NSCLC after prior chemotherapy
|
|
June 2015
|
EU approval for the treatment of both first-line and previously treated unresectable or metastatic melanoma patients, regardless of BRAF status
|
|
March 2015
|
FDA approval for the treatment of patients with advanced SQ NSCLC with progression on or after platinum-based chemotherapy
|
|
Opdivo
+
Yervoy
(ipilimumab)
|
September 2015
|
FDA approval for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma
|
Yervoy
|
October 2015
|
FDA approval for the adjuvant treatment of patients with cutaneous melanoma
|
July 2015
|
Japanese Ministry of Health, Labour and Welfare approval for first and second line treatment for unresectable malignant melanoma
|
|
Empliciti
(elotuzumab)
|
November 2015
|
FDA approval for the treatment of multiple myeloma as combination therapy with
Revlimid*
and dexamethasone in patients who have received one to three prior therapies
|
Hepatitis C Portfolio -
Daklinza
(daclatasvir)
|
July 2015
|
FDA approval for use with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3
|
|
|
Year Ended December 31,
|
|
2015 vs. 2014
|
|
2014 vs. 2013
|
||||||||||||||||||
|
|
Total Revenues
|
|
Analysis of % Change
|
|
Analysis of % Change
|
||||||||||||||||||
|
|
|
|
|
|
|
|
Total
|
|
Foreign
|
|
Total
|
|
Foreign
|
||||||||||
Dollars in Millions
|
|
2015
|
|
2014
|
|
2013
|
|
Change
|
|
Exchange
(b)
|
|
Change
|
|
Exchange
(b)
|
||||||||||
United States
|
|
$
|
8,188
|
|
|
$
|
7,716
|
|
|
$
|
8,318
|
|
|
6
|
%
|
|
—
|
|
|
(7
|
)%
|
|
—
|
|
Europe
|
|
3,491
|
|
|
3,592
|
|
|
3,930
|
|
|
(3
|
)%
|
|
(17
|
)%
|
|
(9
|
)%
|
|
—
|
|
|||
Rest of the World
|
|
4,142
|
|
|
3,459
|
|
|
3,295
|
|
|
20
|
%
|
|
(13
|
)%
|
|
5
|
%
|
|
(5
|
)%
|
|||
Other
(a)
|
|
739
|
|
|
1,112
|
|
|
842
|
|
|
(34
|
)%
|
|
N/A
|
|
|
32
|
%
|
|
N/A
|
|
|||
Total
|
|
$
|
16,560
|
|
|
$
|
15,879
|
|
|
$
|
16,385
|
|
|
4
|
%
|
|
(7
|
)%
|
|
(3
|
)%
|
|
(1
|
)%
|
(a)
|
Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
|
(b)
|
Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales.
|
Dollars in Millions
|
|
Charge-Backs and Cash Discounts
|
|
Medicaid and Medicare Rebates
|
|
Sales Returns
|
|
Other Rebates, Discounts and Adjustments
|
|
Total
|
||||||||||
Balance at January 1, 2014
|
|
$
|
49
|
|
|
$
|
286
|
|
|
$
|
279
|
|
|
$
|
324
|
|
|
$
|
938
|
|
Provision related to sale made in:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Current period
|
|
755
|
|
|
574
|
|
|
94
|
|
|
776
|
|
|
2,199
|
|
|||||
Prior period
|
|
—
|
|
|
(23
|
)
|
|
(33
|
)
|
|
(10
|
)
|
|
(66
|
)
|
|||||
Returns and payments
|
|
(748
|
)
|
|
(570
|
)
|
|
(105
|
)
|
|
(711
|
)
|
|
(2,134
|
)
|
|||||
Foreign currency translation and other
|
|
—
|
|
|
—
|
|
|
(3
|
)
|
|
(27
|
)
|
|
(30
|
)
|
|||||
Balance at December 31, 2014
|
|
$
|
56
|
|
|
$
|
267
|
|
|
$
|
232
|
|
|
$
|
352
|
|
|
$
|
907
|
|
Provision related to sale made in:
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Current period
|
|
1,043
|
|
|
878
|
|
|
109
|
|
|
1,206
|
|
|
3,236
|
|
|||||
Prior period
|
|
—
|
|
|
(19
|
)
|
|
(73
|
)
|
|
(23
|
)
|
|
(115
|
)
|
|||||
Returns and payments
|
|
(1,002
|
)
|
|
(688
|
)
|
|
(85
|
)
|
|
(782
|
)
|
|
(2,557
|
)
|
|||||
Foreign currency translation and other
|
|
—
|
|
|
(4
|
)
|
|
(2
|
)
|
|
(44
|
)
|
|
(50
|
)
|
|||||
Balance at December 31, 2015
|
|
$
|
97
|
|
|
$
|
434
|
|
|
$
|
181
|
|
|
$
|
709
|
|
|
$
|
1,421
|
|
|
|
Year Ended December 31,
|
||||||||||
Dollars in Millions
|
|
2015
|
|
2014
|
|
2013
|
||||||
Gross product sales
|
|
$
|
17,166
|
|
|
$
|
13,793
|
|
|
$
|
14,391
|
|
Gross-to-Net Adjustments
|
|
|
|
|
|
|
||||||
Charge-backs and cash discounts
|
|
(1,043
|
)
|
|
(755
|
)
|
|
(717
|
)
|
|||
Medicaid and Medicare rebates
|
|
(859
|
)
|
|
(551
|
)
|
|
(490
|
)
|
|||
Sales returns
|
|
(36
|
)
|
|
(61
|
)
|
|
(62
|
)
|
|||
Other rebates, discounts and adjustments
|
|
(1,183
|
)
|
|
(766
|
)
|
|
(818
|
)
|
|||
Total Gross-to-Net Adjustments
|
|
(3,121
|
)
|
|
(2,133
|
)
|
|
(2,087
|
)
|
|||
Net product sales
|
|
$
|
14,045
|
|
|
$
|
11,660
|
|
|
$
|
12,304
|
|
•
|
Charge-backs and cash discounts increased in 2015 primarily due to higher product sales in the U.S., particularly regarding
Eliquis
and
Opdivo
.
|
•
|
Medicaid and Medicare rebates increased in 2015 primarily due to higher product sales and rebate rates in the U.S., particularly Medicare for
Eliquis.
Medicaid and Medicare rebates increased in 2014 primarily due to higher Medicare sales and rebate rates for
Eliquis
, and higher Medicaid rebates on virology products due to price increase limitations, partially offset by the diabetes business divestiture in February 2014.
|
•
|
The U.S. sales return reserve for
Plavix*
was reduced by $63 million in 2015, $30 million in 2014 and $22 million in 2013 after considering several factors including actual return experience and estimated inventory levels in the distribution channels. In accordance with Company policy, these products are eligible to be returned between six months prior to and twelve months after product expiration. The U.S. sales return reserve for
Plavix*
was not material at December 31, 2015.
|
•
|
Other rebates, discounts and adjustments increased in 2015 primarily due to additional rebates and discounts for
Daklinza
(including approximately $180 million upon obtaining final pricing in France for amounts deferred through March 31, 2015) and
Eliquis
.
|
|
|
Year Ended December 31,
|
|
% Change
|
|
% Change Attributable to
Foreign Exchange
|
||||||||||||||||||
Dollars in Millions
|
|
2015
|
|
2014
|
|
2013
|
|
2015 vs. 2014
|
|
2014 vs. 2013
|
|
2015 vs. 2014
|
|
2014 vs. 2013
|
||||||||||
Virology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Baraclude (entecavir)
|
|
$
|
1,312
|
|
|
$
|
1,441
|
|
|
$
|
1,527
|
|
|
(9
|
)%
|
|
(6
|
)%
|
|
(7
|
)%
|
|
(2
|
)%
|
U.S.
|
|
135
|
|
|
215
|
|
|
289
|
|
|
(37
|
)%
|
|
(26
|
)%
|
|
—
|
|
|
—
|
|
|||
Non-U.S.
|
|
1,177
|
|
|
1,226
|
|
|
1,238
|
|
|
(4
|
)%
|
|
(1
|
)%
|
|
(9
|
)%
|
|
(2
|
)%
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Hepatitis C Franchise
(daclatasvir and asunaprevir)
|
|
1,603
|
|
|
256
|
|
|
—
|
|
|
**
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|||
U.S.
|
|
323
|
|
|
—
|
|
|
—
|
|
|
N/A
|
|
|
N/A
|
|
|
—
|
|
|
—
|
|
|||
Non-U.S.
|
|
1,280
|
|
|
256
|
|
|
—
|
|
|
**
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Reyataz (atazanavir sulfate) Franchise
|
|
1,139
|
|
|
1,362
|
|
|
1,551
|
|
|
(16
|
)%
|
|
(12
|
)%
|
|
(5
|
)%
|
|
(1
|
)%
|
|||
U.S.
|
|
591
|
|
|
689
|
|
|
769
|
|
|
(14
|
)%
|
|
(10
|
)%
|
|
—
|
|
|
—
|
|
|||
Non-U.S.
|
|
548
|
|
|
673
|
|
|
782
|
|
|
(19
|
)%
|
|
(14
|
)%
|
|
(11
|
)%
|
|
(3
|
)%
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Sustiva (efavirenz) Franchise
|
|
1,252
|
|
|
1,444
|
|
|
1,614
|
|
|
(13
|
)%
|
|
(11
|
)%
|
|
—
|
|
|
—
|
|
|||
U.S.
|
|
1,041
|
|
|
1,118
|
|
|
1,092
|
|
|
(7
|
)%
|
|
2
|
%
|
|
—
|
|
|
—
|
|
|||
Non-U.S.
|
|
211
|
|
|
326
|
|
|
522
|
|
|
(35
|
)%
|
|
(38
|
)%
|
|
(1
|
)%
|
|
—
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
Empliciti (elotuzumab)
|
|
3
|
|
|
—
|
|
|
—
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|||
U.S.
|
|
3
|
|
|
—
|
|
|
—
|
|
|
N/A
|
|
|
N/A
|
|
|
—
|
|
|
—
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|